Claims
- 1. A polyclonal antibody to a cytochrome P450 retinoic acid metabolizing peptide comprising the amino acid sequence of SEQ. ID. NO. 5.
- 2. The polyclonal antibody of claim 1 to an immunogenic portion or epitope of SEQ. ID. NO. 5.
- 3. A method for inhibiting P450RAI-2 induced retinoic acid hydroxylation in an organism or an in vitro system by administering the antibody of claims 1 or 2 to the organism or the in vitro system.
- 4. A method for inhibiting P450RAI-2 induced retinoic acid hydroxylation in an organism or in an in vitro system comprising administering to the organism or the in vitro system an effective amount of an antisense nucleic acid or oligonucleotide substantially complementary to at least a portion of the sequence identified as SEQ ID NO:4.
- 5. The method of claim 4 wherein the portion is at least 5 bases in length, or at least about 10 bases in length, or at least about 15 bases in length, or at least about 20 bases in length, or at least about 25 bases in length, or at least about 30 bases in length, or at least about 35 bases in length, or at least about 40 bases in length, or at least about 45 bases in length, or at least about 50 bases in length.
- 6. The method of claim 3. 4 or 5 wherein the organism is human.
- 7. The method of claim 3 or 4 wherein the organism is being treated for a disease selected from the group consisting of cancer, actinic keratosis, oral leukoplakia, a secondary tumor of the head and/or neck, a non-small cell lung carcinoma, a basal cell carcinoma, acute promyelocytic leukemia, skin cancer, and a premalignancy associated actinic keratosis, acne, psoriasis and/or ichthyosis.
- 8. The method of claim 7 wherein the disease is acute promyelocytic leukemia.
- 9. The method of claim 7 wherein the disease is lung cancer.
- 10. The method fo claim 9 wherein the lung cancer is non- small cell lung cancer.
- 11. A method for the screening of the expression of P450RAI-2 in a sample, comprising exposing the sample to an antibody of claims 1 or 2 and assaying for the presence P450RAI-2 and antibody interaction.
- 12. The method fo claim 11, wherein the antibody is a labeled antibody to enable detection of binding and non-binding to a P450RAI-2 substrate.
- 13. The method of claim 11 whrein the assay is an ELISA assay.
- 14. A kit for determining the presence of a P450RAI-2 protein containing an amino acid sequence as identified by SEQ ID NO: 5 comprising an antibody to said protein linked to a reporter system, wherein the reporter system produces a detectable response when a predetermined amount of the protein and the antibody are bound together.
- 15. The kit of claim 14 wherein the antibody is the antibody of claim 1 or 2.
- 16. The kit of claim 14 wherein said protein comprises the amino acid sequence identified as SEQ ID NO:5.
- 17. A method for determining the presence of a first said nucleic acid molecule of SEQ. ID. NO. 4, the kit comprising a second nucleic acid molecule capable of hybridizing with at least a portion of a the first nucleic acid molecule under the high stringency conditions of (a), in which the second nucleic acid molecule is linked to a reporter system wherein the reporter system produces a detectable response when a predetermined amount of the first and second molecules are hybridized together.
- 18. A kit for determining the presence of a first said nucleic acid molecule of SEQ. ID. NO. 4, the kit comprising a second nucleic acid molecule capable of hybridizing with at least a portion of a the first nucleic acid molecule under the high stringency conditions of (a), in which the second nucleic acid molecule is linked to a reporter system wherein the reporter system produces a detectable response when a predetermined amount of the first and second molecules are hybridized together.
- 19. The kit of claim 17 wherein the second nucleic acid molecule is at least 5 bases in length, or at least about 10 bases in length, or at least about 15 bases in length, or at least about 20 bases in length, or at least about 25 bases in length, or at least about 30 bases in length, or at least about 35 bases in length, or at least about 40 bases in length, or at least about 45 bases in length, or at least about 50 bases in length.
- 20. The methods of claim 11 or 17 for diagnosing non small lung cell carcinoma in a patient.
- 21. The kit of claim 14 or 18 for the diagnosis of non small lung cell carcinoma in a patient.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT CA00/01493 |
Dec 2000 |
CA |
|
PRIOR APPLICATIONS
[0001] This application claims priority from Patent Cooperation Treaty patent application No. PCT/CA 00/01493 filed Dec. 15, 2000, which is incorporated herein by reference. As Dec. 15, 2001 falls on a Saturday, this application is being filed on the next available business day, Monday Dec. 17, 2001, in accordance with Article 4 of the Stockholm Act of the Paris Convention for the Prtoection of Industrial Property and Article 18 of the Patent Cooperation Treaty.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/CA01/01805 |
12/17/2001 |
WO |
|